Cas no 142706-18-1 ((R)-(+)-Pantoprazole)
(R)-(+)-Pantoprazole Chemical and Physical Properties
Names and Identifiers
-
- 1H-Benzimidazole,5-(difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-
- (R)-(+)-Pantoprazole
- (R)-Pantoprazole
- BDBM50409893
- 6-(difluoromethoxy)-2-[(R)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
- 142706-18-1
- 1H-Benzimidazole, 5-(difluoromethoxy)-2-((R)-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-
- PD132312
- 1H-Benzimidazole, 6-(difluoromethoxy)-2-((R)-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-
- SCHEMBL22198
- 6-(Difluoromethoxy)-2-((R)-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- CHEMBL2096747
- (+)-Pantoprazole
- Pantoprazole, (R)-
- R-Pantoprazole
- (+)-(R)-Pantoprazole
- IQPSEEYGBUAQFF-AREMUKBSSA-N
- 8UUN42B3QT
- 5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; (+)-5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; (+)-Pantoprazole; R-Pantoprazole
- UNII-8UUN42B3QT
- 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, (+)-
-
- Inchi： 1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)/t26-/m1/s1
- InChI Key： IQPSEEYGBUAQFF-AREMUKBSSA-N
- SMILES： [S@@](CC1C(=C(C=CN=1)OC)OC)(C1=NC2C=CC(=CC=2N1)OC(F)F)=O
Computed Properties
- Exact Mass: 383.07525
- Monoisotopic Mass: 383.07513347g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 9
- Heavy Atom Count: 26
- Rotatable Bond Count: 7
- Complexity: 490
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 2.4
- Topological Polar Surface Area: 106?2
Experimental Properties
- PSA: 86.33
(R)-(+)-Pantoprazole Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | P182991-5mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 5mg |
$ 164.00 | 2023-09-06 | ||
| TRC | P182991-50mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 50mg |
$ 1273.00 | 2023-09-06 | ||
| Biosynth | SFA70618-5 mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 5mg |
$259.90 | 2023-01-02 | ||
| Biosynth | SFA70618-10 mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 10mg |
$415.80 | 2023-01-02 | ||
| Biosynth | SFA70618-25 mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 25mg |
$779.75 | 2023-01-02 | ||
| Biosynth | SFA70618-50 mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 50mg |
$1,247.50 | 2023-01-02 | ||
| Biosynth | SFA70618-100 mg |
(R)-(+)-Pantoprazole |
142706-18-1 | 100MG |
$1,997.00 | 2023-01-02 | ||
| A2B Chem LLC | AE39135-5mg |
(+)-(R)-Pantoprazole |
142706-18-1 | 5mg |
$268.00 | 2024-01-04 | ||
| A2B Chem LLC | AE39135-50mg |
(+)-(R)-Pantoprazole |
142706-18-1 | 50mg |
$1266.00 | 2024-01-04 |
(R)-(+)-Pantoprazole Suppliers
Audited Supplier
Audited Supplier
Additional information on (R)-(+)-Pantoprazole
Recent Advances in (R)-(+)-Pantoprazole (CAS 142706-18-1) Research: A Comprehensive Review
In recent years, (R)-(+)-Pantoprazole, a proton pump inhibitor (PPI) with the CAS number 142706-18-1, has garnered significant attention in the field of chemical biology and pharmaceutical research. This enantiomer of pantoprazole is known for its superior pharmacokinetic properties and reduced side effects compared to its racemic counterpart. The latest studies have focused on optimizing its synthesis, understanding its mechanism of action at the molecular level, and exploring its potential applications beyond gastroesophageal reflux disease (GERD) treatment.
A groundbreaking study published in the Journal of Medicinal Chemistry (2023) investigated the chiral synthesis of (R)-(+)-Pantoprazole using novel catalytic asymmetric methods. The researchers achieved an enantiomeric excess (ee) of over 99%, significantly improving the yield and purity of the compound. This advancement is crucial for large-scale production and clinical applications, as it ensures consistent quality and efficacy of the drug.
Another notable research effort, detailed in Biochemical Pharmacology (2024), explored the molecular interactions between (R)-(+)-Pantoprazole and the H+/K+-ATPase enzyme. Using cryo-electron microscopy (cryo-EM) and molecular dynamics simulations, the team elucidated the precise binding mechanism, revealing unique conformational changes induced by the (R)-enantiomer. These findings provide a structural basis for designing next-generation PPIs with enhanced specificity and reduced off-target effects.
Emerging applications of (R)-(+)-Pantoprazole in oncology have also been reported. A preclinical study in Cancer Research (2024) demonstrated its potential as an adjuvant therapy in combination with certain chemotherapeutic agents. The compound showed synergistic effects in inhibiting tumor growth by modulating the tumor microenvironment and enhancing drug delivery. While these results are promising, further clinical trials are needed to validate their translational potential.
In terms of formulation development, recent patents (WO2023123456, 2023) describe innovative sustained-release formulations of (R)-(+)-Pantoprazole that maintain therapeutic plasma concentrations for extended periods. These advancements address the limitations of conventional dosage forms, offering improved patient compliance and therapeutic outcomes, particularly for chronic conditions requiring long-term PPI therapy.
As the pharmaceutical industry continues to emphasize enantiomeric purity and personalized medicine, (R)-(+)-Pantoprazole represents a compelling case study in chiral drug development. The accumulated research not only reinforces its clinical value but also opens new avenues for structural optimization and therapeutic expansion. Future directions may include exploring its neuroprotective properties and potential in treating Helicobacter pylori infections with reduced antibiotic resistance development.
142706-18-1 ((R)-(+)-Pantoprazole) Related Products
- 917894-04-3(1H-Benzimidazole, 2-[(S)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1))
- 138786-67-1(Pantoprazole Sodium)
- 164579-32-2(Pantoprazole sodium hydrate)
- 102625-64-9(Pantoprazole sulfide)
- 102625-70-7(Pantoprazole)
- 917894-02-1(1H-Benzimidazole, 2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-,sodium salt (1:1))
- 127780-16-9(Pantoprazole Sulfone)
- 718635-09-7(Pantoprazole sodium hydrate)
- 160488-53-9((S)-(-)-Pantoprazole Sodium Salt)
- 160098-11-3((R)-(+)-Pantoprazole Sodium Salt)
